Published in Proc Natl Acad Sci U S A on November 01, 1973
Expression of the viral thymidine kinase gene in herpes simplex virus-transformed L cells. J Virol (1974) 2.15
Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev (2001) 1.49
Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob Agents Chemother (1978) 1.46
Neoplasms, differentiations and mutations. Am J Pathol (1974) 1.30
The latent herpes simplex virus. Bacteriol Rev (1974) 1.00
Aetiology of oral cancer in patients less than or equal to 30 years of age. Br J Cancer (1989) 0.92
A review of primate herpes viruses. Proc R Soc Med (1975) 0.90
Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: A meta-analysis. Biomed Rep (2013) 0.83
Are viruses important in carcinogenesis? Am J Pathol (1974) 0.78
The role of immunology in the diagnosis, prognosis and treatment planning of oral cancer. Proc R Soc Med (1976) 0.75
Herpes simplex-genitalis virus nonvirion antigens and their implication in certain human cancers: unconfirmed. Proc Natl Acad Sci U S A (1974) 0.75
SPECIFIC ADENOVIRUS COMPLEMENT-FIXING ANTIGENS IN VIRUS-FREE HAMSTER AND RAT TUMORS. Proc Natl Acad Sci U S A (1963) 10.02
SYNTHESIS OF SV40 TUMOR ANTIGEN DURING REPLICATION OF SIMIAN PAPOVAVIRUS (SV40). Proc Natl Acad Sci U S A (1964) 5.23
SOURCE OF GENETIC INFORMATION FOR SPECIFIC COMPLEMENT-FIXING ANTIGENS IN SV40 VIRUS-INDUCED TUMORS. Proc Natl Acad Sci U S A (1964) 4.78
IMMUNOFLUORESCENT STUDIES OF ADENOVIRUS 12 TUMORS AND OF CELLS TRANSFORMED OR INFECTED BY ADENOVIRUSES. J Exp Med (1964) 4.33
BEHAVIOR OF NONINFECTIOUS SV 40 VIRAL GENOME IN HAMSTER TUMOR CELLS: INDUCTION OF SYNTHESIS OF INFECTIOUS VIRUS. Proc Natl Acad Sci U S A (1963) 3.87
DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS. J Exp Med (1965) 3.36
PRODUCTION OF "TUMOR-SPECIFIC" ANTIGENS BY ONCOGENIC VIRUSES DURING ACUTE CYTOLYTIC INFECTIONS. Proc Natl Acad Sci U S A (1965) 3.18
A DNA fragment of Herpes simplex 2 and its transcription in human cervical cancer tissue. Proc Natl Acad Sci U S A (1972) 2.45
Virus-specific, labile, nonvirion antigen in herpesvirus-infected cells. Proc Natl Acad Sci U S A (1970) 2.04
Soluble membrane antigens of lip and cervical carcinomas: reactivity with antibody for herpesvirus nonvirion antigens. Science (1973) 0.98
Increase in preexisting cellular antigen-combining groups at different times after infection with different viruses. Proc Natl Acad Sci U S A (1970) 0.93
Serologic surveys of human cancer patients for antibody to adenovirus T antigens. Am J Epidemiol (1970) 0.90
Nonvirion antigens produced by herpes simplex viruses 1 and 2. Proc Natl Acad Sci U S A (1973) 0.90
Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science (1948) 19.46
IDENTIFICATION OF THE FILTRABLE, TRANSMISSIBLE NEUROLYTIC AGENT ISOLATED FROM TOXOPLASMA-INFECTED TISSUE AS A NEW PLEUROPNEUMONIA-LIKE MICROBE. Science (1938) 11.12
TOXOPLASMA AND OBLIGATE INTRACELLULAR PARASITISM. Science (1937) 6.75
ISOLATION OF A FILTRABLE, TRANSMISSIBLE AGENT WITH "NEUROLYTI" PROPERTIES FROM TOXOPLASMA-INFECTED TISSUES. Science (1938) 5.54
AN ACQUIRED RESISTANCE OF GROWING ANIMALS TO CERTAIN NEUROTROPIC VIRUSES IN THE ABSENCE OF HUMORAL ANTIBODIES OR PREVIOUS EXPOSURE TO INFECTION. J Exp Med (1936) 5.38
MICE AS CARRIERS OF PATHOGENIC PLEUROPNEUMONIA-LIKE MICROORGANISMS. Science (1939) 4.76
EXPERIMENTAL PROLIFERATIVE ARTHRITIS IN MICE PRODUCED BY FILTRABLE, PLEUROPNEUMONIA-LIKE MICROORGANISMS. Science (1939) 4.64
PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. Science (1945) 4.05
THE THERAPEUTIC EFFECTIVENESS OF A PRACTICALLY NONTOXIC NEW COMPOUND (CALCIUM AUROTHIOMALATE) IN EXPERIMENTAL, PROLIFERATIVE, CHRONIC ARTHRITIS OF MICE. Science (1940) 3.63
INSECTS AND EPIDEMIOLOGY OF POLIOMYELITIS. Science (1942) 3.59
Visceral lesions in infectious polyneuritis: (Infectious neuronitis, acute polyneuritis with facial diplegia, guillain-barré syndrome, landry's paralysis). Am J Pathol (1941) 3.52
FLIES AS CARRIERS OF POLIOMYELITIS VIRUS IN URBAN EPIDEMICS. Science (1941) 3.48
Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis (1985) 2.64
Virus-specific, labile, nonvirion antigen in herpesvirus-infected cells. Proc Natl Acad Sci U S A (1970) 2.04
Paralytic poliomyelitis: Old dogmas and new perspectives. Rev Infect Dis (1981) 1.62
Amantadine hydrochloride. Analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. JAMA (1967) 1.52
POLIOMYELITIS IN A LABORATORY WORKER EXPOSED TO THE VIRUS. Science (1941) 1.48
Mortality from pneumonia and risk conditions during influenza epidemics. High influenza morbidity during nonepidemic years. JAMA (1977) 1.40
NUTRITION AS A FACTOR IN THE DEVELOPMENT OF CONSTITUTIONAL BARRIERS TO INVOLVEMENT OF THE NERVOUS SYSTEM BY CERTAIN VIRUSES. Science (1940) 1.28
Behaviour of Chimpanzee-avirulent Poliomyelitis Viruses in Experimentally Infected Human Volunteers. Br Med J (1955) 1.23
Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA (1965) 1.20
Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses. Eur J Epidemiol (1991) 1.15
Amantadine and influenza: evaluation of conflicting reports. J Infect Dis (1978) 1.15
Vaccination against poliomyelitis in economically underdeveloped countries. Bull World Health Organ (1980) 1.12
Perspectives on current use of some virus vaccines in the USA. Measles, rubella, poliomyelitis, and influenza in the USA: contrasts in control by vaccination. Pediatr Res (1979) 1.09
Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A (1992) 1.04
Detection of early antigens in nuclei of cells infected with cytomegalovirus or herpes simplex virus type 1 and 2 by anti-complement immunofluorescence, and use of a blocking assay to demonstrate their specificity. Int J Cancer (1977) 1.00
Reproductive capacity and viability at higher temperatures of various transformed hamster cell lines. J Natl Cancer Inst (1969) 0.99
Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev Infect Dis (1984) 0.98
Soluble membrane antigens of lip and cervical carcinomas: reactivity with antibody for herpesvirus nonvirion antigens. Science (1973) 0.98
Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control. Eur J Epidemiol (1991) 0.95
Poliomyelitis vaccination. Evaluation and direction in continuing application. Am J Clin Pathol (1978) 0.94
Increase in preexisting cellular antigen-combining groups at different times after infection with different viruses. Proc Natl Acad Sci U S A (1970) 0.93
Immunization against measles by aerosol. Rev Infect Dis (1983) 0.92
Herpes simplex virus nuclear nonvirion antigens detected by anticomplement immunofluorescence. Tumori (1977) 0.92
The Presence of Poliomyelitis Virus in Human Cases and Carriers During the Winter. Yale J Biol Med (1944) 0.91
Nonvirion antigens produced by herpes simplex viruses 1 and 2. Proc Natl Acad Sci U S A (1973) 0.90
Vaccine-associated poliomyelitis cases. Bull World Health Organ (1969) 0.90
Nature and source of mycoplasma in various tissue cultures. Ann N Y Acad Sci (1967) 0.88
MULTIPLICATION AND SPREAD OF THE VIRUS OF ST. LOUIS ENCEPHALITIS IN MICE WITH SPECIAL EMPHASIS ON ITS FATE IN THE ALIMENTARY TRACT. J Exp Med (1947) 0.88
High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J Infect Dis (1985) 0.87
CONSTITUTIONAL BARRIERS TO INVOLVEMENT OF THE NERVOUS SYSTEM BY CERTAIN VIRUSES. Science (1940) 0.86
Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br Med J (Clin Res Ed) (1986) 0.86
Different effects of chloramphenicol, dactinomycin, and streptovitacin A on synthesis of tumor and virion antigens in SV40 virus-infected cells. Proc Natl Acad Sci U S A (1966) 0.84
Varicella-zoster virus vaccine. JAMA (1977) 0.84
Inadequate serological surveys for immunity to poliomyelitis. Inadequate indicators of immune status of communities using oral poliovirus vaccine and inadequate guides to vaccination policy. Med J Aust (1983) 0.84
[Papular purpuric gloves and socks syndrome. A case report]. Minerva Pediatr (2004) 0.83
Overview and horizons in prevention of some human infectious diseases by vaccination. Am J Clin Pathol (1978) 0.83
Appearance in trypsinized normal cells of reactivity with antibody presumably specific for malignant cells. Proc Natl Acad Sci U S A (1973) 0.82
Cell-mediated immunity to herpes simplex virus types 1 and 2 antigens in leukoplakia and carcinoma in man. Oncology (1976) 0.82
Effectiveness of AIDS vaccines. Science (1991) 0.81
Further studies on an immunoenzymatic assay for herpes simplex virus tumor-associated antigen. Clin Immunol Immunopathol (1982) 0.80
Genetic phenomena in experimental viral carcinogenesis. Search for such phenomena in cancers of children. Am J Dis Child (1966) 0.80
Clinical trials of inhaled aerosol of human diploid and chick embryo measles vaccine. Lancet (1982) 0.80
Collaboration for accelerating progress in medical research. Science (1967) 0.80
Residual paralytic poliomyelitis in a tropical region of Brazil, 1969-1977: prevalence surveys in different age groups as indicators of changing incidence. Am J Epidemiol (1983) 0.80
Human tumor antigens inducing in vivo delayed hypersensitivity and in vitro mitogenic activity. Oncology (1983) 0.79
[On the inactivating action in vitro of some ketoaldehyde derivatives on arboviruses]. Boll Soc Ital Biol Sper (1964) 0.79
Suppression of malignancy in human cancer cells: issues and challenges. Proc Natl Acad Sci U S A (1981) 0.78
[On the inactivating action in vitro of some ketoaldehyde derivatives on encephalomyocarditis (EMC) virus and aphthous (FMD) virus]. Boll Soc Ital Biol Sper (1964) 0.78
Vaccine control of poliomyelitis in the 1980s. Yale J Biol Med (1983) 0.78
My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics (1992) 0.77
Immunization: Evaluation of some currently available and prospective vaccines. JAMA (1981) 0.76
Editorial: Misery of recurrent herpes: what to do? N Engl J Med (1975) 0.76
Are the herpes simplex-genitalis viruses a cause of certain human cancers? Adv Pathobiol (1976) 0.76
An immune enzymatic assay for purified tumour associated antigen of herpes simplex virus. Cell Mol Biol Incl Cyto Enzymol (1979) 0.76
HIV vaccination dilemma. Nature (1993) 0.76
Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. 1960. Bull World Health Organ (1999) 0.76
Herpes simplex-genitalis virus nonvirion antigens and their implication in certain human cancers: unconfirmed. Proc Natl Acad Sci U S A (1974) 0.75
Studies of tumor-specific and herpesvirus nonvirion antigens. Cancer Res (1974) 0.75
Viral hepatitis: problems of incidence and control in military personnel. Yale J Biol Med (1976) 0.75
A STUDY OF THE THERAPEUTIC MECHANISM OF ANTI-PNEUMOCOCCIC SERUM ON THE EXPERIMENTAL DERMAL PNEUMOCOCCUS INFECTION IN RABBITS : III. THE INFLUENCE OF NON-SPECIFIC FACTORS. J Exp Med (1933) 0.75
Viral Infections of the Human Nervous System: Classification and General Considerations. Postgrad Med J (1950) 0.75
Medicine and public health in Baltimore during the early years of the Sinai Hospital of Baltimore. Md Med J (1991) 0.75
Properties of a virus variant derived from drug-treated mice infected with A-PR8 influenza virus. Antimicrob Agents Chemother (Bethesda) (1965) 0.75
[Histologic characteristics of infection caused by the virus of urine dermatomyositis]. Acta Neurol (Napoli) (1966) 0.75
Priorities in research. Science (1993) 0.75
[Problems of influenza vaccination]. Fortschr Med (1981) 0.75
Current challenges in medical practice and research. Md Med J (1992) 0.75
Properties of an avirulent influenza A virus variant derived from drug-treated mice infected with PR8 virus. Arch Gesamte Virusforsch (1966) 0.75
Proceedings: Cancer research in Israel: work of academic institutions and National Cancer Registry. Natl Cancer Inst Monogr (1974) 0.75
[Vaccination against poliomyelitis in developing countries]. Salud Publica Mex (1980) 0.75
[Current and prospective study of non-structural herpesvirus antigens]. G Mal Infett Parassit (1971) 0.75
Reflections on the qualitative and quantitative aspects of neurovirulence of different polioviruses. Dev Biol Stand (1993) 0.75
Effect of streptovitacin A on replication of an RNA virus (poliovirus). Proc Soc Exp Biol Med (1967) 0.75
Absence of risk of human immunodeficiency virus (HIV) infection in recipients of hepatitis B vaccine. Eur J Epidemiol (1987) 0.75
Acceptance of the Howland award. Pediatr Res (1974) 0.75
[Description of the methods for culture in acellular media of PPLO (pleuropneumonia-like organisms)]. Boll Soc Ital Biol Sper (1964) 0.75
Judaism and Medicine. Perspect Biol Med (1983) 0.75
[Cytomegalovirus and herpes simplex virus antibodies in patients with idiopathic ulcerative rectocolitis]. Minerva Med (1990) 0.75
Studies on the mechanism of antiviral activity of ketoaldehyde derivatives of biphenyl. Chemotherapy (1966) 0.75
Round table discussion on "Unifying concepts of leukemia and related neoplasms in man and animals leading to eventual control and prevention". Concluding remarks of the chairman. Bibl Haematol (1973) 0.75
Multiple sclerosis--a critique and prospective. Adv Neurol (1974) 0.75